Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-17T07:41:00.361Z Has data issue: false hasContentIssue false

EPA-0235 – Effectiveness of Long-acting Injectable Antipsychotics (Pplai and Rlai) in the Treatment of Delusional Disorder with Non-prominent Hallucinations

Published online by Cambridge University Press:  15 April 2020

A. González-Rodríguez
Affiliation:
Psychiatry, Hospital Clinic de Barcelona, Barcelona, Spain
O. Molina-Andreu
Affiliation:
Psychiatry, Hospital Universitari Mútua de Terrassa, Terrassa, Spain
R. Penadés
Affiliation:
Psychiatry, Schizophrenia Unit. Institute Clinic of Neurosciences. Hospital Clinic of Barcelona., Barcelona, Spain
M. Bernardo Arroyo
Affiliation:
Psychiatry, Schizophrenia Unit. Institute Clinic of Neurosciences. Hospital Clinic of Barcelona., Barcelona, Spain
R. Catalán
Affiliation:
Psychiatry, Schizophrenia Unit. Institute Clinic of Neurosciences. Hospital Clinic of Barcelona., Barcelona, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction:

Recent meta-analysis in schizophrenia report that patients treated with long-acting injectable antipsychotics (LAI) show a significant improvement in hallucinations. However, little evidence supports their efficacy in non-prominent hallucinations in delusional disorder (DD) patients.

Objectives:

To examine treatment effectiveness of LAI antipsychotics (PPLAI and RLAI) with other oral antipsychotics in DD with non-prominent hallucinations.

Methods:

A prospective and observational study was carried out by including 60 consecutive cases of DD outpatients, as part of the DEVCODEL Study. All patients were followed up for at least 6 months. Outcome variables: Scores in PANSS, HRSD-17 items, PSP for functionality, and C-SSRS for suicide. To investigate whether differences between treatment groups were biased by confounding variables, scores in assessment scales at 6 months served as dependent variables, and hallucinatory and treatment groups were included as between-subject factors when analysis of covariance (ANCOVA) was applied.

Results:

24(40%) patients had non-prominent hallucinations. Although not statistically significant, when uncorrected for influencing factors, DD patients receiving PPLAI or RLAI (n=27;45.5%) were less frequently treated with antidepressants (32%vs.68%) and showed lower suicidality (44.4%vs.55.6%). Patients treated with PPLAI or RLAI had lower scores in psychotic symptoms and suicidal ideation intensity, and higher functionality. After adjustment, patients with non-prominent hallucinations receiving PPLAI or RLAI showed a tendency of improvement in functionality, lower scores in PANSS positive (p=0.003) and negative (p=0.047) subscales, and suicidal ideation severity (p<0.001) compared to those treated with oral antipsychotics.

Conclusions:

Non-prominent hallucinatory patients treated with PPLAI or RLAI showed a significant improvement in psychopathology and suicidal ideation.

Type
EPW01 - Schizophrenia 1
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.